Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ABVC BIOPHARMA, INC. (ABVC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 · Dec 31 | 2017 · Sep 30 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296,000 | $0 | $152,430 | $969,783 | $355,797 | $483,045 | $701,719 | $6,956 | — | — | — | $3,360 | — | $7,787 | $5,714 | $3,190 | $14,860 |
| Gross profit | — | $508,826 | −$149,607 | $683,368 | $350,711 | $464,329 | $681,582 | −$178,324 | — | — | −$32 | $2,839 | — | — | — | — | — |
| Research & development | $121,085 | $179,272 | $1.1M | $2.7M | $1.0M | $549,658 | $1.0M | $988,721 | $3.2M | $3.2M | $10.0M | — | — | — | — | — | — |
| Operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M | $9.0M | $4.1M | $2.6M | $4.1M | — | — | $35,120 | — | $185,046 | $1.1M | $1.9M | — |
| Operating income | −$7.2M | −$4.7M | −$6.8M | −$15.1M | −$11.7M | −$8.5M | −$3.5M | −$2.8M | −$4.1M | −$4.0M | −$11.0M | — | — | −$177,259 | −$1.1M | −$1.9M | −$1.9M |
| EBITDAderived | — | — | — | −$15.1M | −$11.7M | — | — | — | — | — | — | — | — | −$153,400 | −$1.1M | −$1.9M | −$1.8M |
| Net income | −$7.9M | −$4.9M | −$7.8M | −$16.4M | −$12.8M | −$10.6M | −$3.9M | −$6.1M | −$4.2M | −$4.1M | −$11.0M | −$32,281 | −$23,235 | −$226,352 | −$1.1M | −$1.2M | −$1.9M |
| Basic EPSper diluted share | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$0.51 | -$0.50 | -$0.21 | -$0.02 | -$0.02 | -$0.02 | -$0.06 | -$0.01 | — | $0.00 | -$0.04 | -$0.31 | -$0.47 |
| Diluted EPSper diluted share | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$0.51 | -$0.50 | -$0.21 | -$0.02 | -$0.02 | -$0.02 | -$0.06 | -$0.01 | — | $0.00 | -$0.04 | -$0.31 | -$0.47 |